var data={"title":"Fluoxetine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluoxetine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6216?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">see &quot;Fluoxetine: Drug information&quot;</a> and <a href=\"topic.htm?path=fluoxetine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluoxetine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708805\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluoxetine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Appropriately monitor and closely observe patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoxetine is approved for use in children with MDD (aged 8 years and older) and obsessive-compulsive disorder (OCD; aged 7 years and older). Sarafem is not approved for use in children.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172714\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>PROzac;</li>\n      <li>PROzac Weekly [DSC];</li>\n      <li>Sarafem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172715\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Fluoxetine;</li>\n      <li>Ava-Fluoxetine;</li>\n      <li>CO Fluoxetine;</li>\n      <li>Dom-Fluoxetine;</li>\n      <li>Fluoxetine Capsules BP;</li>\n      <li>FXT 40;</li>\n      <li>Gen-Fluoxetine;</li>\n      <li>JAMP-Fluoxetine;</li>\n      <li>Mint-Fluoxetine;</li>\n      <li>Mylan-Fluoxetine;</li>\n      <li>Novo-Fluoxetine;</li>\n      <li>Nu-Fluoxetine;</li>\n      <li>PHL-Fluoxetine;</li>\n      <li>PMS-Fluoxetine;</li>\n      <li>PRO-Fluoxetine;</li>\n      <li>Prozac;</li>\n      <li>Q-Fluoxetine;</li>\n      <li>ratio-Fluoxetine;</li>\n      <li>Riva-Fluoxetine;</li>\n      <li>Sandoz-Fluoxetine;</li>\n      <li>Teva-Fluoxetine;</li>\n      <li>ZYM-Fluoxetine </li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052928\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052920\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">see &quot;Fluoxetine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anxiety  with associated phobias and panic attacks:</b> Very limited data available: Children 2 to 6 years: Oral: 5 mg/dose or 0.25 mg/kg/dose once daily; adequate trial is considered to be 8 to 10 weeks; continuation of therapy should be evaluated at 6 to 9 months after initiation; dosing based on case report in a 2.5-year old child and expert recommendations (Gleason 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bulimia nervosa adjunct therapy with cognitive behavioral therapy:</b> Limited data available: Children &ge;12 years and Adolescents: Oral: Initial: 20 mg once daily for 3 days, then 40 mg once daily for 3 days, then 60 mg once daily; dosing based on an open-label study of 10 pediatric patients (age: 12 to 18 years) which showed significant decrease in number of weekly purges; other reports describe use in adolescents (Gable 2005; Kotler 2003; Rosen 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;8 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lower weight Children: Oral: Initial: 10 mg once daily; usual daily dose: 10 mg/<b>day</b>; if needed, may increase dose to 20 mg once daily after several weeks; maximum daily dose: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Higher weight Children and Adolescents: Oral: Initial: 10 to 20 mg once daily; in patients started at 10 mg once daily, may increase dose to 20 mg after 1 week; maximum daily dose: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available: Lower initial dosing has been recommended by some experts (Dopheide 2006; Gleason 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;11 years: Oral: Initial: 5 mg once daily; clinically, doses have been titrated up to 40 mg once daily in pediatric patients</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral: Initial: 10 mg once daily; clinically, doses have been titrated up to 40 mg once daily in pediatric patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression associated with bipolar I disorder (in combination with olanzapine):</b> Children &ge;10 years and Adolescents: Oral: Initial: 20 mg in the evening; adjust dose, if needed, as tolerated; safety of fluoxetine doses &gt;50 mg in combination with doses &gt;12 mg of olanzapine has not been studied in pediatrics. <b>Note:</b> When using individual components of fluoxetine with olanzapine rather than fixed-dose combination product (Symbyax), approximate dosage correspondence is as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax 3/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 20 mg = Symbyax 6/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax 12/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 50 mg = Symbyax 6/50</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax 12/50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Obsessive-compulsive disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;7 years: Limited data available: Oral: Initial: 5 mg once daily (Gleason 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;7 years and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lower weight Children: Initial: 10 mg once daily; if needed, may increase dose after several weeks; usual daily dose: 20 to 30 mg/<b>day</b>; minimal experience with doses &gt;20 mg/<b>day</b>; no experience with doses &gt;60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Higher weight Children and Adolescents: Initial: 10 mg once daily; increase dose to 20 mg once daily after 2 weeks; may increase dose after several more weeks, if needed; usual daily dose: 20 to 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Repetitive behavior associated with autism spectrum disorders (ASD):</b> Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 2.5 mg once daily for 7 days; then may titrate at weekly intervals using weight-based dosing: 0.3 mg/kg/<b>day</b> during week 2; followed by 0.5 mg/kg/<b>day</b> during week 3, up to a maximum of 0.8 mg/kg/<b>day</b>; dosing based on a double-blind, crossover, placebo-controlled trial in 39 pediatric patients (age: 5 to 16 years) which showed statistically significant improvement in behavior scores compared to placebo; mean final dose: 9.9 mg/<b>day</b> (range: 2.4 to 20 mg/<b>day</b>) or 0.36 &plusmn; 0.116 mg/kg/<b>day</b> (Hollander 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Selective mutism:</b> Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 5 mg once daily for 7 days, then increase to 10 mg daily for 7 days, and then increase to 20 mg daily;  may further titrate in 20 mg/<b>day</b> increments if needed every 2 weeks; maximum daily dose: 60 mg/<b>day</b>. Dosing is based on an open-label study of 21 pediatric patients (age: 5 to 14 years); positive responses were reported in 76% of patients and required a dose of at least 20 mg/<b>day</b>; mean final dose: 28.1 mg/<b>day</b> (1.1 mg/kg/<b>day</b>) (Dummitt 1996). Weight-based dosing has been reported in a double-blind placebo-controlled trial (treatment group: n=6; placebo: n=9; age: 6-12 years) using the following titration: 0.2 mg/kg/<b>day</b> for 1 week, then 0.4 mg/kg/<b>day</b> for 1 week, then 0.6 mg/kg/<b>day</b> for 10 weeks; mean final dose: 21.4 mg/<b>day</b> (Black1994). To fully assess therapeutic response, a therapeutic trial of at least 9 to 12 weeks or longer has been suggested (Black 1994; Dummitt 1996; Kaakeh 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of fluoxetine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Do not initiate fluoxetine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving fluoxetine and potential benefits outweigh potential risks, discontinue fluoxetine promptly and administer linezolid or IV methylene blue. Monitor for serotonin syndrome for 5 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume fluoxetine 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression, obsessive-compulsive disorder:</b> Oral: 20 mg/ day in the morning; may increase after several weeks by 20 mg/day increments; maximum: 80 mg/day; doses &gt;20 mg may be given once daily or divided twice daily. <b>Note:</b> Lower doses of 5 to 10 mg/day have been used for initial treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Bulimia nervosa:</b> Oral: 60 mg once daily; may titrate dose to 60 mg over several days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Depression:</b> Oral: Initial: 20 mg once daily; may increase after several weeks if inadequate response (maximum: 80 mg/<b>day</b>). Patients maintained on Prozac 20 mg/day may be changed to Prozac Weekly 90 mg/week, starting dose 7 days after the last 20 mg/day dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Depression associated with bipolar disorder (in combination with olanzapine):</b> Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20 to 50 mg/<b>day</b>. See <b>&quot;Note&quot;</b> below.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Obsessive-compulsive disorder:</b> Oral: Initial: 20 mg once daily; may increase after several weeks if inadequate response; recommended range: 20 to 60 mg/<b>day</b> (maximum daily dose: 80 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Panic disorder:</b> Oral: Initial: 10 mg once daily; after 1 week, increase to 20 mg/<b>day</b>; may increase after several weeks; doses &gt;60 mg/<b>day</b> have not been evaluated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Premenstrual dysphoric disorder (Sarafem):</b> Oral: 20 mg once daily continuously <b>or</b> 20 mg once daily starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Treatment-resistant depression (in combination with olanzapine):</b> Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20 to 50 mg/<b>day</b>. See <b>&quot;Note&quot;</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> When using individual components of fluoxetine with olanzapine rather than fixed dose combination product (Symbyax), approximate dosage correspondence is as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax 3/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 20 mg = Symbyax 6/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax 12/25</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 5 mg + fluoxetine 50 mg = Symbyax 6/50</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax 12/50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of fluoxetine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Do not initiate fluoxetine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving fluoxetine and potential benefits outweigh potential risks, discontinue fluoxetine promptly and administer linezolid or IV methylene blue. Monitor for serotonin syndrome for 5 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume fluoxetine 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults: Adjustment not routinely needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single dose studies: Adults: Pharmacokinetics of fluoxetine and norfluoxetine were similar among subjects with all levels of impaired renal function, including anephric patients on chronic hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic administration: Additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Not removed by hemodialysis; use of lower dose or less frequent dosing is not usually necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cirrhosis patient: Administer a lower dose or less frequent dosing interval</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Compensated cirrhosis without ascites: Administer 50% of normal dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172686\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PROzac: 10 mg, 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PROzac Weekly: 90 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 90 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/5 mL (5 mL, 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sarafem: 10 mg, 20 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172670\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7873368\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Fluoxetine tablets: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202133s004s005lbl.pdf#page=40&amp;token=KAq0HFpd0VBG9LMTauTFBOWYc/isG2TSgwvqT4uhUvEzemge7eBMmHq6UJ0JumOOS5ZxEKvzFt8+c6kalP+EJ/aYk56JIAUNwb8E6FbcUaHbdoKc8sIbgXlnA7nGoQSH&amp;TOPIC_ID=13315\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202133s004s005lbl.pdf#page=40</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Prozac and Prozac Weekly: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s103,021235s023lbl.pdf#page=28&amp;token=STpzTjylQZzpbtwBxCvaobO7lqxqj9r/oG/R4S/iasBi3SgqnFtnIbVmwSmKA5t5rpE4Hrm1XeYTlfc/4P3DlIln5DJPvd9ERQ68OrK+FOi+bGywBmGCQcMh+up3WIBx&amp;TOPIC_ID=13315\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s103,021235s023lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sarafem: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021860s011lbl.pdf#page=33&amp;token=aQbMmwiugzHLsHnPdh7dL+UcmYooopLAgySxjKSn2B7hUMalSJVIS+BeKZW/6Flu3PLynpUyJgNOWJZrBS25yWfvkoGKQOwlNblQDk7N7cM9dQ0RrCsQ4MMCDLImbfiE&amp;TOPIC_ID=13315\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021860s011lbl.pdf#page=33</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052933\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indication specific:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Major depressive disorder and obsessive compulsive disorder: Take in the morning; if twice daily dosing, take at morning and noon</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bipolar I disorder and treatment-resistant depression (with concurrent olanzapine): Take in the evening   </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bulimia: Take in the morning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172708\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">All dosage forms should be stored at controlled room temperature. Protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052932\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment (acute and maintenance) of major depressive disorder (FDA approved in ages &ge;8 years and adults); depressive episodes associated with bipolar I disorder (in combination with olanzapine) (FDA approved in ages &ge;10 years and adults); treatment (acute and maintenance) of obsessive-compulsive disorder (FDA approved in ages &ge;7 years and adults); treatment of bulimia nervosa (FDA approved in adults); treatment of panic disorder with or without agoraphobia (FDA approved in adults); treatment of  premenstrual dysphoric disorder (PMDD) (Sarafem: FDA approved in adults); has also been used for anxiety and/or selective mutism and repetitive behavior associated with an autism spectrum disorder (eg, autism, Asperger's syndrome, pervasive developmental disorders) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172774\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">FLUoxetine may be confused with DULoxetine, famotidine, Feldene, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, Loxitane [DSC], PARoxetine, thiothixene, vortioxetine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PROzac may be confused with Paxil, Prelone, PriLOSEC, Prograf, Proscar, ProSom, Provera</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Sarafem may be confused with Serophene</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) is identified in the Beers Criteria as a potentially inappropriate medication because of their association with falls and fractures and should be avoided in patients 65 years and older with a history of falls or fractures. In addition, the SSRIs should be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [U.S., Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172770\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in adults, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, hypertension, palpitations, prolonged Q-T interval on ECG (QTcF &ge;450 msec<sup>3</sup>), vasodilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormality in thinking, agitation (children and adolescents), amnesia, anxiety, chills, confusion, dizziness, drowsiness, emotional lability, headache, insomnia, nervousness, personality disorder (children and adolescents), sleep disorder, yawning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hypermenorrhea (children and adolescents), increased thirst (children and adolescents), weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia, dyspepsia, flatulence, increased appetite, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Ejaculatory disorder, impotence, urinary frequency (children and adolescents), urination disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Hyperkinesia (children and adolescents), tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis (children and adolescents), flu-like symptoms, pharyngitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acne vulgaris, acute abdominal condition, akathisia, albuminuria, alopecia, amenorrhea, anaphylactoid reaction, anemia, angina pectoris, angle-closure glaucoma, aphthous stomatitis, aplastic anemia, arthritis, asthma, ataxia, atrial fibrillation, bruise, bruxism, bursitis, cardiac arrhythmia, cardiac failure, cataract, cerebrovascular accident, cholelithiasis, cholestatic jaundice, colitis, dehydration, delusions, depersonalization, dyskinesia, dysphagia, dysuria, ecchymoses, edema, eosinophilic pneumonitis, equilibrium disturbance, erythema multiforme, erythema nodosum, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal reaction (rare), gastritis, gastroenteritis, gastrointestinal ulcer, glossitis, gout, gynecological bleeding, gynecomastia, hallucination, hemolytic anemia (immune-related), hepatic failure, hepatic necrosis, hepatitis, hiccups, hostility, hypercholesteremia, hyperprolactinemia, hypersensitivity reaction, hypertonia, hyperventilation, hypoglycemia, hypokalemia, hyponatremia (possibly in association with SIADH), hypotension, hypothyroidism, immune thrombocytopenia, laryngeal edema, laryngospasm, leg cramps, lupus-like syndrome, malaise, melena, memory impairment, migraine, mydriasis, myocardial infarction, myoclonus, neuroleptic malignant syndrome (Stevens 2008), optic neuritis, orthostatic hypotension, ostealgia, pancreatitis, pancytopenia, paranoia, petechia, priapism, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, purpuric rash, renal failure, serotonin syndrome, sexual disorder (may persist after discontinuation), skin photosensitivity, Stevens-Johnson syndrome, suicidal ideation, syncope, tachycardia, thrombocytopenia, toxic epidermal necrolysis, vasculitis, ventricular tachycardia (including torsades de pointes), violent behavior</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172694\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently, within 5 weeks of discontinuing fluoxetine, or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (<b>Note:</b> Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Initiation of fluoxetine within 2 weeks of thioridazine discontinuation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172674\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders; </b>consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor all patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with health care provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. <b>Fluoxetine is FDA approved for the treatment of OCD in children &ge;7 years of age and MDD in children &ge;8 years of age.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic events and rash: Fluoxetine use has been associated with occurrences of significant rash and allergic events, including vasculitis, lupus-like syndrome, laryngospasm, anaphylactoid reactions, and pulmonary inflammatory disease. Discontinue if underlying cause of rash cannot be identified.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anticholinergic effects: Relatively devoid of these side effects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: May cause insomnia, anxiety, nervousness, or anorexia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular effects: May cause mild pupillary dilation, which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; QT prolongation: QT prolongation and ventricular arrhythmia including torsade de pointes has occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of prolonged QT, family history of prolonged QT or sudden cardiac death), other conditions that predispose to arrhythmias (eg, hypokalemia, hypomagnesemia, recent MI, uncompensated heart failure, bradyarrhythmias or other arrhythmias, concomitant use of other agents that prolong QT interval), or increased fluoxetine exposure (eg, overdose, hepatic impairment, use of CYP2D6 inhibitors, poor CYP2D6 metabolizer status, concomitant use of other highly protein-bound drugs). Consider ECG monitoring when initiating therapy in patients with risk factors for QT prolongation and ventricular arrhythmia. Consider discontinuing fluoxetine if ventricular arrhythmia suspected and initiate cardiac evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St. John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk. Consider discontinuation if symptomatic hyponatremia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Weight loss: May cause anorexia and/or weight loss. Use caution in patients where weight loss is undesirable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with a history of MI or unstable heart disease; experience in these patients is limited.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glycemic control and may require adjustment of antidiabetic medication; hypoglycemia and hyperglycemia has been observed during and after cessation of therapy, respectively. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed in patients with cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Fluoxetine monotherapy is not FDA approved for the treatment of bipolar depression.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; a lower dosage or less frequent dosing may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a previous seizure disorder or conditions predisposing to seizures such as brain damage or alcoholism. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: May also cause agitation, sleep disturbances, and excessive CNS stimulation in older adults. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, light-headedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddad 2001; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Long half-life: Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820100\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer 2006). SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer 2006). May cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); use with caution in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, or other drugs that affect coagulation. A recent report describes five children (age: 8 to 15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake 2000). Fluoxetine may cause decreased growth (smaller increases in weight and height) in children and adolescent patients; currently, no studies directly evaluate fluoxetine's long-term effects on growth, development, and maturation of pediatric patients; periodic monitoring of height and weight in pediatric patients is recommended. Case reports of decreased growth in children receiving fluoxetine or fluvoxamine (n=4; age: 11.6 to 13.7 years) for 6 months to 5 years suggest a suppression of growth hormone secretion during SSRI therapy (Weintrob 2002). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172756\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172679\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13315&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: FLUoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers. <b> Exceptions: </b>Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP2D6 inhibitor; this recommendation does not apply if treating major depressive disorder.  Reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the adverse/toxic effect of FLUoxetine. BuPROPion may increase the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone. Management: The combination of a selective serotonin reuptake inhibitor and buspirone should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: FLUoxetine may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May enhance the QTc-prolonging effect of FLUoxetine. Clarithromycin may increase the serum concentration of FLUoxetine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a moderate CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inhibitors): CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Ajmaline; Dapoxetine; Indoramin; Tamoxifen; Timolol (Ophthalmic); Tropisetron.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dosulepin: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dosulepin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Fosphenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: FLUoxetine may enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome. Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: FLUoxetine may enhance the adverse/toxic effect of NIFEdipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: FLUoxetine may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: FLUoxetine may enhance the QTc-prolonging effect of Pimozide. FLUoxetine may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Reuptake Inhibitor/Antagonists: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin Reuptake Inhibitor/Antagonists. This may cause serotonin syndrome.  Management: Consider alternatives, and use conservative initial dosing.  Monitor patients receiving these combinations for signs/symptoms of serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: FLUoxetine may enhance the QTc-prolonging effect of Thioridazine. FLUoxetine may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: FLUoxetine may enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluoxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Vortioxetine.  Management: The vortioxetine dose should be reduced by 50% when used together with a strong CYP2D6 inhibitor.  Following cessation of the strong CYP2D6 inhibitor, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ziprasidone: FLUoxetine may enhance the QTc-prolonging effect of Ziprasidone. Ziprasidone may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172681\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172698\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Fluoxetine and its metabolite cross the human placenta. Available studies evaluating teratogenic effects following maternal use of fluoxetine in the first trimester have shown inconsistent results. An increased risk of cardiovascular events was observed in one study; however, no specific pattern was observed and a causal relationship has not been established. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of in utero SSRI exposure on infant development and behavior are not known.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of fluoxetine to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052927\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function, weight, serum glucose; serum sodium (in volume depleted patients); monitor for rash and signs or symptoms of anaphylactoid reactions; monitor height and weight in pediatric patients periodically. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052931\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Therapeutic levels have not been well established:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapeutic: Fluoxetine 100 to 800 ng/mL (SI: 289-2314 nmol/L); norfluoxetine 100 to 600 ng/mL (SI: 289 to 1,735 nmol/L) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Toxic: (Fluoxetine plus norfluoxetine): &gt;2,000 ng/mL (SI: &gt;5,784 nmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172673\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172693\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8 to 12 weeks after initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed; delayed 1 to 2 hours with weekly formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 12 to 43 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 95% to albumin and alpha<sub>1</sub> glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP2C19 and 2D6, to norfluoxetine (activity equal to fluoxetine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Parent drug: 1 to 3 days (acute), 4 to 6 days (chronic), 7.6 days (cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metabolite (norfluoxetine): 9.3 days (range: 4 to 16 days), 12 days (cirrhosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">\n      <b>Note:</b> Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily. Average steady-state concentrations of once-daily dosing were highest in children ages 6 to &lt;13 (fluoxetine 171 ng/mL; norfluoxetine 195 ng/mL), followed by adolescents ages 13 to &lt;18 (fluoxetine 86 ng/mL; norfluoxetine 113 ng/mL); concentrations were considered to be within the ranges reported in adults (fluoxetine 91 to 302 ng/mL; norfluoxetine 72 to 258 ng/mL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46679675\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Average steady-state fluoxetine serum concentrations in children (n=10; 6 to &lt;13 years of age) were 2-fold higher than in adolescents (n=11; 13 to &lt;18 years of age); all patients received 20 mg/day; average steady-state norfluoxetine serum concentrations were 1.5-fold higher in the children compared with adolescents; differences in weight almost entirely explained the differences in serum concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172692\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Commercial oral solution is available (4 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 1 mg/mL fluoxetine oral solution may be prepared using the commercially available preparation (4 mg/mL). In separate graduated cylinders, measure 5 mL of the commercially available fluoxetine preparation and 15 mL of Simple Syrup, NF. Mix thoroughly in incremental proportions. For a 2 mg/mL solution, mix equal proportions of both the commercially available fluoxetine preparation and Simple Syrup, NF. Label &quot;refrigerate&quot;. Both concentrations are stable for up to 56 days.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172697\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (FLUoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (4): $156.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (FLUoxetine HCl (PMDD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (28): $220.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (28): $225.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (FLUoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $259.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $266.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $160.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (PROzac Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,776.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,825.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $1,095.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (FLUoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/5 mL (120 mL): $118.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (FLUoxetine HCl (PMDD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $487.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $487.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (FLUoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $86.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $126.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $313.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sarafem Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (7): $167.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (7): $167.23</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172701\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actan (CL, PY);</li>\n      <li>Actisac (TH);</li>\n      <li>Adef-XL (LK);</li>\n      <li>Adep (PH);</li>\n      <li>Adepssir (PH);</li>\n      <li>Adofen (ES);</li>\n      <li>Anextin (QA);</li>\n      <li>Ansi (ID);</li>\n      <li>Ansilan (CO);</li>\n      <li>Antiprestin (ID);</li>\n      <li>Auscap (AU);</li>\n      <li>Bellzac (IE);</li>\n      <li>Biozac (BG);</li>\n      <li>Boniflox (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Captaton (AR);</li>\n      <li>Daforin (BR);</li>\n      <li>Dagrilan (GR);</li>\n      <li>Dawnex (LK, ZW);</li>\n      <li>Deprexin (BM, BS, BZ, GY, HU, JM, SR, TT);</li>\n      <li>Deprizac (PH);</li>\n      <li>Deproxin (TH);</li>\n      <li>Dominium (EC);</li>\n      <li>Drafzin (PH);</li>\n      <li>Elizac (ID);</li>\n      <li>Flocept (ET);</li>\n      <li>Floxet (HK, HU, UY);</li>\n      <li>Fluctin (DE);</li>\n      <li>Fluctine (AT, CH);</li>\n      <li>Fludac (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Fludec (LK);</li>\n      <li>Fluketin (SG);</li>\n      <li>Fluksen (UA);</li>\n      <li>Flunil (IN);</li>\n      <li>Fluohexal (AU);</li>\n      <li>Fluovex (MY);</li>\n      <li>Fluox (NZ);</li>\n      <li>Fluox-Puren (DE);</li>\n      <li>Fluoxeren (IT);</li>\n      <li>Fluoxone (SG);</li>\n      <li>Fluronin (TW);</li>\n      <li>Flush (BD);</li>\n      <li>Flutin (AE, CO, KW, MY, QA, SA);</li>\n      <li>Flutine (TH);</li>\n      <li>Fluval (HR);</li>\n      <li>Flux (LV);</li>\n      <li>Fluxen (TW);</li>\n      <li>Fluxet (DE);</li>\n      <li>Fluxetin (HK);</li>\n      <li>Fluxil (AE, BH, CY, IQ, IR, JO, KW, LB, LY, MT, OM, SA, SG, SY, TR, YE);</li>\n      <li>Fluzac (BD, IE);</li>\n      <li>Fontex (DK, FI, IS, NO, SE);</li>\n      <li>Fropine (KR);</li>\n      <li>Fuloren (KR);</li>\n      <li>Fuxetine (KR);</li>\n      <li>Gerozac (IE);</li>\n      <li>Huma-Fluoxetin (HU);</li>\n      <li>Lanclic (KR);</li>\n      <li>Lorien (ZA);</li>\n      <li>Lovan (AU);</li>\n      <li>Lugtils (VN);</li>\n      <li>Luramon (ES);</li>\n      <li>Margrilan (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, PH, SA, SG, SY, YE);</li>\n      <li>Modipran (BD);</li>\n      <li>Moltoben (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Motivest (PH);</li>\n      <li>Neupax (CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Nopres (ID);</li>\n      <li>Nuzak (ZA);</li>\n      <li>Nycoflox (EE);</li>\n      <li>Olena (GB);</li>\n      <li>Oxactin (MT);</li>\n      <li>Oxedep (CN);</li>\n      <li>Oxetin (BD);</li>\n      <li>Oxetine (AE, JO, LB, QA, SA);</li>\n      <li>Plazeron (MT);</li>\n      <li>Portal (HR, HU);</li>\n      <li>Praxin (HU);</li>\n      <li>Prazac (KR);</li>\n      <li>Prizma (IL);</li>\n      <li>Prodep (IN, UA);</li>\n      <li>Prolert (LK);</li>\n      <li>Prozac (AE, AR, AU, BB, BE, BF, BH, BJ, BR, CI, CL, CN, CZ, EG, ES, ET, FR, GB, GH, GM, GN, HK, HR, HU, IE, IL, IT, JO, KE, KR, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, NE, NG, NL, NZ, PE, PK, PT, QA, RO, RU, SA, SC, SD, SG, SK, SL, SN, TH, TN, TR, TZ, UG, VE, VN, ZM, ZW);</li>\n      <li>Prozac 20 (KR, MY, PH, TW);</li>\n      <li>Prozac Dispersible (KR);</li>\n      <li>Prozac Weekly (BB, KR);</li>\n      <li>Prozit (TR);</li>\n      <li>Qualisac (HK);</li>\n      <li>Reneuron (ES);</li>\n      <li>Salipax (BM, BS, BZ, GY, JM, MY, PL, QA, SR, TT);</li>\n      <li>Seronil (FI);</li>\n      <li>Sinzac (TW);</li>\n      <li>Symbyax (MX);</li>\n      <li>U-Zet (TW);</li>\n      <li>Youke (CN);</li>\n      <li>ZAC (ID);</li>\n      <li>Zactin (AU, SG, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/23879318/pubmed\" target=\"_blank\" id=\"23879318\">23879318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/22299006/pubmed\" target=\"_blank\" id=\"22299006\">22299006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Black B and Uhde TW, &ldquo;Treatment of Elective Mutism With Fluoxetine: A Double Blind, Placebo-Controlled Study,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 1994, 33(7):1000-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/7961338/pubmed\" target=\"_blank\" id=\"7961338\">7961338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo; <i>N Engl J Med</i>, 2006, 354(6):579-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16467545 /pubmed\" target=\"_blank\" id=\"16467545 \">16467545 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeSilva KE, Le Flore DB, Marston BJ, et al, &ldquo;Serotonin Syndrome in HIV-Infected Individuals Receiving Antiretroviral Therapy and Fluoxetine,&rdquo; <i>AIDS</i>, 2001, 15(10):1281-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/11426073/pubmed\" target=\"_blank\" id=\"11426073\">11426073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, &quot;Recognizing and Treating Depression in Children and Adolescents,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(3):233-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16434782/pubmed\" target=\"_blank\" id=\"16434782\">16434782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow SP, Sonies BC, Scheib D, et al, &quot;Practical Guidelines for the Assessment and Treatment of Selective Mutism,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(7):836-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/7649953/pubmed\" target=\"_blank\" id=\"7649953\">7649953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dummit ES 3rd, Klein RG, Tancer NK, et al, &quot;Fluoxetine Treatment of Children With Selective Mutism: An Open Trial,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1996, 35(5):615-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/8935208/pubmed\" target=\"_blank\" id=\"8935208\">8935208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gable KN and Dopheide JA, &ldquo;Psychotropic Medication Use at a Private Eating Disorders Treatment Facility: A Retrospective Chart Review and Descriptive Data Analysis,&rdquo; <i>Curr Ther Res Clin Exp</i>, 2005, 66:572-88.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gleason MM, Egger HL, Emslie GJ, et al, &quot;Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(12):1532-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/18030077/pubmed\" target=\"_blank\" id=\"18030077\">18030077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander E, Phillips A, Chaplin W, et al, &quot;A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism,&quot; <i>Neuropsychopharmacology</i>, 2005, 30(3):582-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/15602505/pubmed\" target=\"_blank\" id=\"15602505\">15602505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaakeh Y and Stumpf JL, &quot;Treatment of Selective Mutism: Focus on Selective Serotonin Reuptake Inhibitors,&quot; <i>Pharmacotherapy</i>, 2008, 28(2):214-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/18225967/pubmed\" target=\"_blank\" id=\"18225967\">18225967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kotler LA, Devlin MJ, Davies M, et al, &quot;An Open Trial of Fluoxetine for Adolescents With Bulimia Nervosa,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2003, 13(3):329-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/14642021/pubmed\" target=\"_blank\" id=\"14642021\">14642021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2000, 10(1):35-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/10755580/pubmed\" target=\"_blank\" id=\"10755580\">10755580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(6):1253-1255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/8282672/pubmed\" target=\"_blank\" id=\"8282672\">8282672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levinson-Castiel R, Merlob P, Linder N, et al, &quot;Neonatal Abstinence Syndrome After <i>in utero</i> Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,&quot; <i>Arch Pediatr Adolesc Med</i>, 2006, 160(2):173-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16461873/pubmed\" target=\"_blank\" id=\"16461873\">16461873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al, &quot;Serotonin Transport and Metabolism in the Mammary Gland Modulates Secretory Activation and Involution,&quot; <i>J Clin Endocrinol Metab</i>, 2010, 95(2):837-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/19965920/pubmed\" target=\"_blank\" id=\"19965920\">19965920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPheeters ML, Warren Z, Sathe N, et al, &quot;A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders,&quot; <i>Pediatrics</i>, 2011, 127(5):e1312-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/21464191/pubmed\" target=\"_blank\" id=\"21464191\">21464191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/22132433/pubmed\" target=\"_blank\" id=\"22132433\">22132433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, Bruy&egrave;re O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosen DS and American Academy of Pediatrics Committee on Adolescence, &quot;Identification and Management of Eating Disorders in Children and Adolescents,&quot; <i>Pediatrics</i>, 2010, 126(6):1240-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/21115584/pubmed\" target=\"_blank\" id=\"21115584\">21115584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Safer DJ and Zito JM, &quot;Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(1/2):159-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16553536/pubmed\" target=\"_blank\" id=\"16553536\">16553536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo; <i>Ann Pharmacother</i>, 2008, 42(9):1290-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/18628446/pubmed\" target=\"_blank\" id=\"18628446\">18628446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taddio A, Ito S, and Koren G, &quot;Excretion of Fluoxetine and its Metabolite, Norfluoxetine, in Human Breast Milk,&quot; <i>J Clin Pharmacol</i>, 1996, 36(1):42-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/8932542/pubmed\" target=\"_blank\" id=\"8932542\">8932542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintrob N, Cohen D, Klipper-Aurbach Y, et al, &ldquo;Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 2002, 156(7):696-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluoxetine-pediatric-drug-information/abstract-text/12090838/pubmed\" target=\"_blank\" id=\"12090838\">12090838</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13315 Version 259.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708805\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172714\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172715\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052928\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052920\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172686\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F172670\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7873368\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052933\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F172708\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052932\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F172774\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172770\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172694\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172674\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820100\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F172756\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172679\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172681\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F172698\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052927\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1052931\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172673\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F172693\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F46679675\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F172692\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F172697\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172701\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13315|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">Fluoxetine: Drug information</a></li><li><a href=\"topic.htm?path=fluoxetine-patient-drug-information\" class=\"drug drug_patient\">Fluoxetine: Patient drug information</a></li></ul></div></div>","javascript":null}